• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Revive Therapeutics Ltd (OP:RVVTF)

    0.0227 +0.0004 (+1.79%)
    Streaming Delayed Price Updated: 3:59 PM EDT, Apr 25, 2025 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    All News about Revive Therapeutics Ltd

    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Revive Therapeutics Announces Proposed Shares for Debt Transaction
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics to Investigate Bucillamine’s Potential in Cancer Treatment
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Acquisition of Molecular Hydrogen Program
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Results of Annual Shareholder Meeting
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    DiagnaMed Granted FDA Orphan Drug Designation for Molecular Hydrogen to Treat Amyotrophic Lateral Sclerosis
    Toronto, Ontario--(Newsfile Corp. - March 3, 2025) - DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) ("DiagnaMed", "DMED", or the "Company"), a leading... 
    Via Newsfile
    Exposures Product Safety
    Revive Therapeutics Announces LOI to Acquire DiagnaMed’s Molecular Hydrogen Program
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Update on R&D Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Publication Demonstrating Novel Therapeutic Approach of Psilocybin in Stroke
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Strategic Focus on Bucillamine for Infectious Diseases and Medical Countermeasures
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure and Expansion into Viral Infections
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    EXCLUSIVE: Legal Magic Mushroom Products Will Be Sold In Jamaica As Psilocybin Products Hit Pharmacy Shelves
    Jamaica introduces its first legal psilocybin products in pharmacies through a historic partnership between PATOO and Fontana Pharmacy. 
    Via Benzinga
    Revive Therapeutics Provides Update on Research Study Evaluating Bucillamine for Nerve Agent Exposure
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update on FDA Type C Meeting for Clinical Study of Bucillamine to Treat Long COVID
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update From FDA Meeting for Long COVID Diagnostic Product
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces FDA Acceptance of Meeting Request for Long COVID Diagnostic Product
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update on Psilocybin Clinical Study for Methamphetamine Use Disorder
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Submits Type C Meeting Request Package to FDA for Clinical Study of Bucillamine to Treat Long COVID
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics To Submit Type C Meeting Request with FDA for Bucillamine to Treat Long COVID
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Corporate Update
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Explores the Use of Bucillamine for Long COVID
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update Evaluating Bucillamine for Nerve Agent Exposure with Defence Research and Development Canada
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Successfully Completes Development of a Novel Lyophilized Formulation of Bucillamine
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Announces Results of Annual General and Special Meeting of Shareholders
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Collaborates with Attwill Medical Solutions for the Clinical and Commercial Development of a Novel Lyophilized Formulation of Bucillamine
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Provides Update of Novel Bucillamine Formulation Development
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Enters into Worldwide Exclusive Agreement with Lawson Health Research Institute to Develop and Commercialize a Novel Long COVID Rapid Test
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    Revive Therapeutics Enters into Agreement with Defence Research and Development Canada for Evaluating Bucillamine for Nerve Agent Exposure
    From Revive Therapeutics Ltd.
    Via GlobeNewswire
    < Previous 1 2 3 4 5 6 7 8 9 10 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms Of Service.